



## **Ophthotech Enrolls First Patient in Phase 3 Clinical Trial of Fovista™ Anti-PDGF Therapy in Combination with Anti-VEGF Therapy for Wet AMD**

**New York, NY – August 29, 2013** – Ophthotech Corporation today announced the initiation of patient enrollment in a pivotal Phase 3 clinical trial of its lead compound Fovista™, an anti-platelet-derived growth factor (PDGF), which is being studied in combination with anti-VEGF therapy for the treatment of newly diagnosed patients with neovascular age-related macular degeneration (wet AMD).

The announcement marks the treatment of the first patient in the global Fovista Phase 3 clinical program, which consists of three clinical trials evaluating the safety and efficacy of the Fovista/anti-VEGF combination. The three trials are expected to enroll a total of approximately 1,866 patients at up to approximately 225 centers internationally.

### **About Ophthotech**

Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat diseases of the eye. The company's most advanced product candidate is Fovista™ anti-PDGF therapy, which it is developing for use in combination with anti-VEGF drugs that represent the standard of care for the treatment of wet age-related macular degeneration. Wet age-related macular degeneration is the leading cause of blindness in patients over the age of 55 in the United States and the European Union. For more information, please visit [www.ophthotech.com](http://www.ophthotech.com).

### **Forward-Looking Statements**

Any statements in this news release about future expectations, plans and prospects for Ophthotech constitute forward-looking statements. Forward-looking statements in this news release include statements regarding the conduct of Ophthotech's Phase 3 clinical program for Fovista in combination with anti-VEGF therapy. Actual results may differ materially from those indicated by such forward-looking statements. Ophthotech anticipates that subsequent events and developments may cause its views to change. However, while Ophthotech may elect to update these forward-looking statements in the future, Ophthotech specifically disclaims any obligation to do so.

### **Contact:**

Jennifer Devine  
SmithSolve LLC on behalf of Ophthotech Corporation  
973-442-1555 ext. 102  
[jennifer.devine@smithsolve.com](mailto:jennifer.devine@smithsolve.com)